Last reviewed · How we verify
Gelusil (ALMASILATE)
Gelusil (generic name: ALMASILATE) is a almasilate drug. It is currently FDA-approved for Gastric Hypersecretory Conditions, Gastroesophageal reflux disease, Heartburn.
At a glance
| Generic name | ALMASILATE |
|---|---|
| Drug class | almasilate |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Approved indications
- Gastric Hypersecretory Conditions
- Gastroesophageal reflux disease
- Heartburn
- Hiatal Hernia with Reflux Esophagitis
- Indigestion
- Peptic ulcer
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gelusil CI brief — competitive landscape report
- Gelusil updates RSS · CI watch RSS
Frequently asked questions about Gelusil
What is Gelusil?
Gelusil (ALMASILATE) is a almasilate drug, indicated for Gastric Hypersecretory Conditions, Gastroesophageal reflux disease, Heartburn.
What is Gelusil used for?
Gelusil is indicated for Gastric Hypersecretory Conditions, Gastroesophageal reflux disease, Heartburn, Hiatal Hernia with Reflux Esophagitis, Indigestion.
What is the generic name of Gelusil?
ALMASILATE is the generic (nonproprietary) name of Gelusil.
What drug class is Gelusil in?
Gelusil belongs to the almasilate class. See all almasilate drugs at /class/almasilate.
What development phase is Gelusil in?
Gelusil is FDA-approved (marketed).
Related
- Drug class: All almasilate drugs
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Gastric Hypersecretory Conditions
- Indication: Drugs for Gastroesophageal reflux disease
- Indication: Drugs for Heartburn
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing